Premier Biomedical Stock Performance
| BIEI Stock | USD 0.0005 0.0001 25.00% |
On a scale of 0 to 100, Premier Biomedical holds a performance score of 1. The company holds a Beta of -0.17, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Premier Biomedical are expected to decrease at a much lower rate. During the bear market, Premier Biomedical is likely to outperform the market. Please check Premier Biomedical's potential upside, day typical price, and the relationship between the total risk alpha and daily balance of power , to make a quick decision on whether Premier Biomedical's historical price patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Premier Biomedical are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady technical and fundamental indicators, Premier Biomedical demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 86.8 K | |
| Total Cashflows From Investing Activities | -4850.00 |
Premier |
Premier Biomedical Relative Risk vs. Return Landscape
If you would invest 0.07 in Premier Biomedical on December 22, 2024 and sell it today you would lose (0.02) from holding Premier Biomedical or give up 28.57% of portfolio value over 90 days. Premier Biomedical is currently generating 0.3433% in daily expected returns and assumes 13.7528% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Premier, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Premier Biomedical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Premier Biomedical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Premier Biomedical, and traders can use it to determine the average amount a Premier Biomedical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.025
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BIEI | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 13.75 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.34 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 1 99% of assets perform better |
Based on monthly moving average Premier Biomedical is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Premier Biomedical by adding it to a well-diversified portfolio.
Premier Biomedical Fundamentals Growth
Premier Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Premier Biomedical, and Premier Biomedical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Premier Pink Sheet performance.
| Return On Asset | -1.54 | |||
| Operating Margin | (22.88) % | |||
| Current Valuation | 1.6 M | |||
| Shares Outstanding | 999.98 M | |||
| Price To Earning | 0.07 X | |||
| Price To Sales | 112.03 X | |||
| Revenue | 14.28 K | |||
| EBITDA | 20.91 K | |||
| Cash And Equivalents | 71.2 K | |||
| Total Debt | 160.75 K | |||
| Debt To Equity | (1.18) % | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (344.18 K) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 100.94 K | |||
| Retained Earnings | (3.91 M) | |||
| Current Asset | 44.58 K | |||
| Current Liabilities | 324.55 K | |||
About Premier Biomedical Performance
By evaluating Premier Biomedical's fundamental ratios, stakeholders can gain valuable insights into Premier Biomedical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Premier Biomedical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Premier Biomedical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. Premier Biomedical, Inc. was founded in 2010 and is headquartered in Jackson Center, Pennsylvania. Premier Biomedical is traded on OTC Exchange in the United States.Things to note about Premier Biomedical performance evaluation
Checking the ongoing alerts about Premier Biomedical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Premier Biomedical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Premier Biomedical had very high historical volatility over the last 90 days | |
| Premier Biomedical has some characteristics of a very speculative penny stock | |
| Premier Biomedical has a very high chance of going through financial distress in the upcoming years | |
| Premier Biomedical currently holds 160.75 K in liabilities. Premier Biomedical has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Premier Biomedical until it has trouble settling it off, either with new capital or with free cash flow. So, Premier Biomedical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Premier Biomedical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Premier to invest in growth at high rates of return. When we think about Premier Biomedical's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 14.28 K. Net Loss for the year was (374.47 K) with profit before overhead, payroll, taxes, and interest of 1.42 K. | |
| Premier Biomedical currently holds about 71.2 K in cash with (344.18 K) of positive cash flow from operations. |
- Analyzing Premier Biomedical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Premier Biomedical's stock is overvalued or undervalued compared to its peers.
- Examining Premier Biomedical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Premier Biomedical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Premier Biomedical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Premier Biomedical's pink sheet. These opinions can provide insight into Premier Biomedical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Premier Pink Sheet analysis
When running Premier Biomedical's price analysis, check to measure Premier Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Premier Biomedical is operating at the current time. Most of Premier Biomedical's value examination focuses on studying past and present price action to predict the probability of Premier Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Premier Biomedical's price. Additionally, you may evaluate how the addition of Premier Biomedical to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |